PARP inhibitors in the ovarian cancer therapy

Abstract

Treatment of the malignant ovarian tumors remains challenging. Some of the reasons are as follows: lack of effective screening technique, usually asymptomatic early stages of the disease, which effects in detecting the disease in advanced stage, and eventually poor prognosis. Treatment of the relapse remains palliative. Inventing new drugs – like PARP inhibitors - gives hope for improvement of the treatment outcomes. This review paper presents actual knowledge on PARP inhibitors in the ovarian cancer therapy.